植入可能なアルギネート- ソルプラス複合器具からのセレコキシブの冷却誘発放出
Romario Lobban1, Michael Carroll2, Victoria Vest1
1Department of Mechanical Engineering, Vanderbilt University, 2201 West End Avenue, Nashville, Tennessee 37235, United States.
ACS biomaterials science & engineering
|August 25, 2025
まとめ
局所的な冷却は,非ステロイド性抗炎症薬 (NSAIDs) をインプラント可能なデバイスから放出させ,オピオイドの代替としてより安全でオンデマンドの痛みを軽減します.
科学分野:
- バイオマテリアル科学
- 薬物の配達
- 痛みの管理
背景:
- オピオイドによる疼痛管理は 依存症の危険性があり より安全な代替手段が必要です
- 非ステロイド性抗炎症薬 (NSAID) は 依存性のない痛みを和らげますが 改善された局所投与方法が必要です
- 現在の外部刺激による薬物放出システムは 経口投与の便利さが欠けている.
研究 の 目的:
- 需要に応じてNSAIDを放出するための新しい冷却誘発薬剤投与システムを開発し,評価する.
- 局所的な冷却を痛み管理のための安全で便利な刺激として使用する可能性を調査する.
- 軽度な冷却によって活性化され,NSAIDの放出を制御できる 植入可能な装置を作成する.
主な方法:
- 低臨界溶液温度 (LCST) 以下の冷却時にゲルから溶液への移行を示す物理的に交結された熱反応性ポリマー水素を用いた.
- NSAID (セレコキシブ) をヒドロゲルに組み込み,非熱反応性膜材料と組み合わせて,埋め込み可能なデポジットを作成します.
- シミュレートされた体液,細胞培養,エクスプラント組織,そして生きた動物の創傷モデルでの冷却誘発放出.
主要な成果:
- ハイドロゲル基の植入器から冷却誘発によるNSAIDの放出が実証されている.
- 軽度な冷却 (29 °C) で薬の放出率を約40倍まで増加させる.
- 生きた動物モデルでトリガーされた放出と有効性の複数のサイクルをサポートするデバイスの機能が確認されました.
結論:
- 局所的な冷却は オンデマンドの薬の投与に 適した刺激です
- 冷却によるNSAIDの放出は,全身的なオピオイド治療に対する有望で中毒性のない代替手段です.
- この技術により 患者は 慣れ親しんだ方法 (アイスパック) を用いて 痛みを和らげることができます
関連する概念動画
01:19Modified-Release Drug Delivery Systems: Overview
243
Modified-release dosage forms are designed to address the limitations of drugs with short biological half-lives. These forms maintain stable therapeutic drug concentrations over extended periods, reducing the need for frequent dosing. A consistent drug level helps minimize peak-trough fluctuations, which can reduce adverse effects, lower the risk of drug resistance, and improve overall treatment effectiveness.One common type of modified-release form is the extended-release (ER) formulation. ER...
243
01:22Modified-Release Drug Delivery Systems: Drug Release Characteristics
265
Drug release from modified-release dosage forms is designed to achieve specific therapeutic effects by controlling the rate and extent of drug release. The classification of these drug release systems is based on key pharmacokinetic assumptions: drug disposition follows first-order kinetics, drug release is the rate-limiting step in absorption, and the released drug is rapidly and completely absorbed.There are four major models of drug release patterns. The first model is the slow zero-order...
265
01:30Modified-Release Drug Delivery Systems: Stimuli-Activated
186
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
186
01:24Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
01:26Oral Drug Delivery Systems: Continuous-Release Systems
323
Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
323
01:11Oral Drug Delivery Systems: Delayed-Release Systems
229
Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
229